Middle East Pharmaceutical Industries Co. (Avalon Pharma) announced on August 18, 2026 the signing of a strategic commercialization agreement with Bio-Thera Solutions Inc. on August 17, 2026, granting Avalon Pharma exclusive rights to register and commercialize Dupilumab, a Proposed Dupixent® Biosimilar, across Saudi Arabia and MENA markets. The 15-year renewable contract also includes rights to localize manufacturing of the product in the future, with a contract value representing less than 5% of the Company's revenues based on the annual financial statements for the year ended December 31, 2025. Subject to no pending patent, the agreement is expected to generate cumulative revenues of no less than SAR 400 million during the first seven years following the anticipated launch in 2031. The partnership strengthens Avalon Pharma's specialty biologics and immunology portfolio and aligns with Saudi Arabia's Vision 2030 localization objectives.

Original announcement:

Attached PDF document link:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.